[Asia Economy Reporter Hyunseok Yoo] T Scientific announced on the 4th that it has decided to acquire Medipron shares worth 15 billion KRW to expand business synergies. After the acquisition, it plans to secure a 10.82% stake.
Medipron is a new drug development specialized bio company developing Alzheimer's dementia treatments, early dementia diagnostic kits, and non-narcotic analgesics. In 2020, it received approval from the Ministry of Food and Drug Safety for Phase 1 clinical trials of a topical analgesic. It is actively conducting business, including obtaining product approval for an Alzheimer's early dementia diagnostic kit jointly developed with Quintamatrix.
As a biotechnology company builder actively expanding its business, T Scientific has secured a foundation to further enhance its new drug development capabilities by acquiring shares in Medipron. In particular, the company expects to create various synergies such as securing new pipelines by establishing diverse collaboration systems with bio companies that have cooperative and investment relationships with T Scientific.
Meanwhile, in November last year, T Scientific additionally acquired shares in TMD Lab, a medical device R&D company specializing in implantable shape-memory polymer materials, securing a total of 20.68% including related parties. After securing the position of the second-largest shareholder, it aims to strengthen business cooperation. Furthermore, it plans to actively promote its business through in-house project discovery and investment, focusing on new drug development, next-generation new drug development verification platform business, and advanced convergence healthcare fields based on artificial intelligence and big data.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
